



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number: **0 288 163 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(49) Date of publication of patent specification: 11.01.95 (51) Int. Cl.<sup>8</sup>: A61K 31/70

(21) Application number: 88302617.1

(22) Date of filing: 24.03.88

The file contains technical information submitted  
after the application was filed and not included in  
this specification

(54) Oligodeoxynucleotides as inhibitors of the replication of retroviruses and the expression of oncogenes.

(30) Priority: 25.03.87 US 30073  
22.02.88 US 159017

(43) Date of publication of application:  
26.10.88 Bulletin 88/43

(45) Publication of the grant of the patent:  
11.01.95 Bulletin 95/02

(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

(56) References cited:  
EP-A- 0 081 099  
EP-A- 0 140 308  
EP-A- 0 169 775

Science vol 235, p.305-311, 16-01-87

PROC. NATL. ACAD. SCI. USA, vol. 84, No-  
vember 1987, p.7706-7710; M. MATSUKURA et  
al.: "Phosphorothioate analogs of oligodeox-  
ynucleotides: Inhibitors of replication and  
cytopathic effects of human Im-  
munodeficiency virus"

(73) Proprietor: THE UNITED STATES OF AMERICA  
as represented by the Secretary United  
States Department of Commerce  
National Technical Information Service,  
Office of Government Inventions and Pat-  
ents,  
5285 Port Royal Road  
Springfield,  
Virginia 22161 (US)

(72) Inventor: Zon, Gerald  
199, Fir Street,  
San Carlos, California 94070 (US)  
Inventor: Shinozuka, Kazuo  
2-6-6 Suwa,  
Kazo City 347, (JP)  
Inventor: Matsukura, Makoto  
263, Congressional Lane, No. T-19,  
Rockville, Maryland 20852, (US)  
Inventor: Cohen, Jack S.,  
6045, Rossmore Drive,  
Bethesda, Maryland 20814 (US)  
Inventor: Neckers, Leonard M.,  
5121, Wissloming Road,  
Bethesda, Maryland 20816 (US)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

EP 0 288 163 B1

NUCLEIC ACIDS RESEARCH, vol. 15, no. 14, July 24, 1987, pp. 5749-5763, IRL Press Limited, Oxford, GB; C.J. MARCUS-SEKURA et al.: "Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alky phosphotriester, methylphosphonate and phosphorothioate linkages"

NATURE, vol. 328, July 30, 1987, pp. 445-449; R. HEIKKILA et al.: "A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1"

JOURNAL OF CHROMATOGRAPHY, vol. 326, June 1985, pp. 263-280, Elsevier Science Publishers B.V., Amsterdam, NL; W.J. STEC et al.: "Reversed-phase high-performance liquid chromatographic separation of diastereomeric phosphorothioate analogues of oligodeoxyribonucleotides and other backbone-modified congeners of DNA"

PROC. NATL. ACAD. SCI. USA, vol. 83, June 1986, pp. 4143-4146; P.C. ZAMECNIK et al.: "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA"

PROC. NATL. ACAD. SCI. USA, vol. 83, May 1986, pp. 2787-2791; C.C. SMITH et al.: "Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5"

PROC. NATL. ACAD. SCI. USA, vol. 83, March 1986, pp. 1911-1915; H. MITSUYA et al.: "Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides"

J. AM. CHEM. SOC., vol. 106, 1984, pp. 6077-6079, US; W.J. STEC et al.: "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides"

Inventor: Loke, Shee Loong,  
11216, Markwood Drive  
Wheaton, Maryland (US)  
Inventor: Stein, Cy Aaron,  
14637, Settlers Landing Way,  
Grithersborg, Maryland 20878, (US)

74 Representative: Daley, Michael John et al  
F.J. CLEVELAND & COMPANY  
40/43 Chancery Lane  
London, WC2A 1JQ (GB)

NUCLEIC ACIDS RESEARCH, vol. 14, no. 24, 1986, pp. 9679-9898, IRL Press Limited, Oxford, GB; K.L. NAKAMAYE et al.: "Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis"

PROC. NATL. ACAD. SCI. USA, vol. 86, no. 20, 1989, pp. 7790-7794, Washington, DC, US; S. AGRAWAL et al.: "Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues"

---

## Description

## FIELD OF THE INVENTION

5 The present invention relates to the inhibition of replication of retroviruses, and is directed more particularly to phosphorothioate oligodeoxyribonucleotide analogs that can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.

## 10 BACKGROUND OF THE INVENTION

Oligodeoxynucleotides, which are complementary to certain gene messages or viral sequences, are referred to as "anti-sense" compounds. These compounds have been reported to have inhibitory effects against Rous sarcoma virus and human T-cell lymphotropic virus type III (HTLV-III), now called Human Immunodeficiency Virus (HIV). However, the susceptibility of the phosphodiester linkage in normal oligodeoxynucleotides to degradation by nucleases would be expected to reduce their potency and *in vivo* persistence as anti-viral agents.

Methylphosphonate-oligodeoxynucleotide analogs are resistant to nucleases, and because they are uncharged have increased hydrophobicity, which reportedly confers increased cell membrane permeability upon these compounds. The methylphosphonate-oligodeoxynucleotides have been found to exhibit antiviral activity, but these compounds may require high concentrations, typically 100-300 micromoles, in order to elicit strong antiviral effects.

A number of investigators have studied the inhibitory properties of both normal oligodeoxynucleotides and analogs of oligodeoxynucleotides. T'so and coworkers evaluated ethyl phosphotriester and methylphosphonate analogs of oligodeoxynucleotides as nonionic compounds that penetrate cells, and are relatively resistant to degradation by nucleases (cf. U.S. Patent No. 4,469,863). The ethyl compounds were found, however, to have the disadvantage of undergoing degradative deethylation in cells. The methylphosphonates were found to be more stable and to have antiviral activity.

The methylphosphonate analogs as described above have been said to inhibit expression of some genes. However, these compounds have a number of serious disadvantages:

- (1) Such compounds are very sensitive to base-catalyzed hydrolysis, making them relatively difficult to synthesize on a routine basis, as compared to polyanionic oligodeoxynucleotides;
- (2) The compounds have relatively low solubility in aqueous media, thus restricting their potential biological/chemotherapeutic usage, as compared to polyanionic oligodeoxynucleotides;
- 35 (3) Relatively high concentrations of these compounds appear to be required to elicit antiviral activity; and
- (4) There is poor hybridization because of the steric effect of the methyl group.

These factors taken together make chemotherapy impractical in humans with these compounds.

Early work by Zamecnik and co-workers used normal unmodified oligodeoxynucleotides, as well as 3'-end-blocked (2',3'-dideoxyribosyl) analogs of oligodeoxynucleotides, to inhibit the transforming ability, replication and translation of Rous sarcoma virus in vitro. This approach has been extended by both Zamecnik et al. in *PNAS, USA*, 83:4143-4146 (1986), who studied the inhibition of HIV virus in cultured human cells, and Wickstrom et al., in *J. Biochem. Biophys. Methods*, 13:97-102 (1986), who investigated the inhibition of the translation of mRNA from vesicular stomatitis virus.

45 Compared to the aforementioned methylphosphonate analogs, the unmodified, or "O", oligodeoxynucleotides offer the advantages of cost-effectiveness and synthetic accessibility, and moreover appear to have the added advantage of lower effective dosages. However, these unmodified oligodeoxynucleotides are susceptible to degradation by nucleases, even with the inclusion of a 3'-end-blocking residue. Consequently, the use of these compounds *in vitro* is significantly restricted, and it is highly unlikely that they can be successful *in vivo*.

The finding that the human T-cell lymphotropic virus type III (HTLV-III), hereinafter referred to as Human Immunodeficiency Virus (HIV), is the causative agent of acquired immune deficiency syndrome (AIDS), prompted considerable interest in the development of chemotherapeutic approaches to the treatment of AIDS. A variety of compounds have been reported to have *in vitro* activity against HIV, although none of these compounds is known to inhibit the expression of the integrated viral genome.

55 The phosphorothioate oligodeoxynucleotides of several sequences, including sense, anti-sense, non-sense, and homo-oligomers, have been found to inhibit HIV, so that the mechanism of inhibition was unclear. Subsequent work has indicated that the inhibition by homo-oligomers, not complementary to any

known sequence in the HIV genome, results from interaction and interference with the function of reverse transcriptase of HIV at low concentrations, i.e. less than 10 micromoles. The mechanism initially expected for complementary base sequence inhibition, known as "translation arrest" of the corresponding mRNA, is apparently not operative in the retrovirus until much higher concentrations of the phosphorothioate compounds are reached, i.e., greater than 25 micromoles. This explains the lack of sequence specificity observed for this inhibitory process.

Attempts have previously been made to inhibit proliferation of normal lymphocytes and HL60 cells using a normal oligodeoxynucleotide (ODN) sequence complementary to a region near the initiation codon of the c-myc gene. Although these results were encouraging, they demonstrated that normal anti-sense c-myc ODNs, even at concentrations as high as 100 micromoles, are not suitable for prolonged inhibition of C-myc protein expression in HL60 cells, even though these normal oligodeoxynucleotides were capable of preventing normal lymphocyte proliferation and c-myc protein expression. It would appear that these insufficiencies of the normal oligodeoxynucleotides, lack of prolonged inhibitory effect and high concentrations required even for short-term effectiveness, were due to enzymatic hydrolysis during the course of the experiment.

Heikkila et al., in Nature, 328, 30 July, 1987, pp. 445-449, disclose that a c-myc oligodeoxynucleotide inhibits entry into the S phase in lymphocyte mitogenesis. Small anti-sense oligomers were added to bulk cell cultures. A pentadecadeoxyribonucleotide complementary to the initiation codon and four downstream codons of human c-myc RNA inhibits mitogen-induced c-myc protein expression in human T-lymphocytes and prevents S phase entry.

#### MATERIAL INFORMATION DISCLOSURE

Japanese patent publication 61 12215 (1983) relates to a method of inhibition of tumor cell growth using oligo DNA.

U.S. Patent 3,687,808 to Merigan, et al., concerns the synthesis of synthetic polynucleotides including thioates.

U.S. Patent 4,511,713 to Miller, et al., concerns inhibiting the replication of foreign nuclei acid with an alkyl or aryl oligonucleotide phosphonate complementary to the indicated sequence of the foreign nuclei acid.

Stec, et al., J. Org. Chem., 50(20):3908-3913, 1985, relates to automatic synthesis of phosphorothioates.

Stec, et al., J. of Chromatography, 326:263-280, 1985; and LaPlanche, et al., Nuclei Acids Research, 14(22):9081-9093, 1986, are related to the preferred present compounds. Stec refers to phosphorothioate analogs of oligodeoxyribonucleotides and LaPlanche concerns phosphorothioate-modified oligodeoxyribonucleotides.

C. C. Smith et al., PNAS, USA, 83:2787-2791 (May 1986), relates to antiviral effect of an oligo (nucleoside methylphosphonate) complementary to the splice junction of Herpes Simplex Virus Type I.


Zamecnik et al., PNAS, USA, 83:4143-4146 (June 1986), concerns inhibition of replication of HTLV-III by exogenous synthetic normal oligonucleotides complementary to viral RNA.

Stec et al. in J. Am. Chem. Soc. 106: 6077, 1984, synthesized phosphorothioate oligodeoxynucleotide analogs.

Broder et al., Proc. Natl. Acad. Sci. USA 84: 7106-7710, 1987.


According to one aspect of the present invention there is provided a pharmaceutical composition comprising a phosphorothioate oligodeoxynucleotide disposed in a pharmaceutically acceptable carrier for use in the prevention of disease caused by replication of foreign nucleic acids in the presence of normal living cells.

In another aspect the invention provides a pharmaceutical compound for the prevention of disease caused by replication of foreign nucleic acids in the presence of normal living cells; of the Formula (I):




20 wherein n is an integer from 5 to 30, B is selected from adenine (A), guanine (G), cytosine (C) and thymidine (T), and X is selected from S and O, with the proviso that at least one X in the compound is S, such that said compound of Formula I is an antisense sequence.

In another aspect, the invention includes a pharmaceutical composition comprising a compound for the inhibition of HTLV-III of Formula II:



45 wherein n is an integer from 5 to 30, and B is selected from adenine (A) guanine (G), cytosine (C) or thymidine (T).

In a different aspect, the invention includes the use in the manufacture of a medicament for the treatment of disease caused by expression of a foreign nucleic acid such as an oncogene or HTLV-III, said medicament comprising a composition comprising a compound of the Formula I:



20 wherein  $n$  is an integer of from 5 to 30,  $B$  is selected from adenine (A), guanine (G), cytosine (C) and thymine (T), and  $X$  is selected from S and O, with the proviso that at least one  $X$  in the compound is S, to provide a specific "anti-sense" sequence to portion of said foreign nucleic acid.

In yet another aspect, the invention provides the use in the manufacture of a composition for the prevention of disease caused by replication of foreign nucleic acids in the presence of normal living cells, comprising phosphorothioate oligodeoxynucleotide in a pharmaceutically acceptable carrier.

The present invention also includes a method for preventing replication of foreign nucleic acid in normal living cells *in vitro* comprising exposing the cells to a replication-inhibiting amount of an oligodeoxynucleotide of Formula I above, wherein  $n$  is an integer from 5 to 30,  $B$  is selected from adenine (A), guanine (G), cytosine (C) and thymine (T), and  $X$  is selected from S and O, with the proviso that at least one  $X$  in the compound is S, such that said compound of Formula I is an antisense sequence, and wherein the oligodeoxynucleotide has a base sequence complementary to a base sequence of human immunodeficiency virus (HIV).

In a different aspect, the present invention includes a method for preventing replication and cytopathic effects of foreign nucleic acid in cells *in vitro* comprising exposing the cells to a replication inhibiting amount of an oligodeoxynucleotide of Formula II above, wherein  $n$  is an integer from 5 to 30, and  $B$  is selected from adenine (A) guanine (G), cytosine (C) or thymine (T).

It is an object of the present invention to overcome deficiencies in the prior art, such as those noted above.

It is another object of the present invention to provide compounds which are effective antiviral agents against retroviruses.

It is yet another object of the present invention to provide compounds which are effective antiviral agents against HIV in human T-cells.


It is a further object of the present invention to inhibit the expression of oncogene product and bring about cessation of cell growth; and still a further object to provide compounds which effect this result.

It is yet a further object of the present invention to inhibit the proliferation of neoplastic cells; and yet another object to provide compounds which can be used as specific treatments to effect this result.

Phosphorothioates are compounds in which one of the non-bridging oxygen atoms in the phosphate portion of the nucleotide is replaced by sulfur. These phosphorothioates have several properties that make them potentially advantageous anti-retroviral analogs. These compounds are stable to cleavage by nucleases, and, since they have the same number of charges as normal oligodeoxynucleotides, have good aqueous solubility. These compounds also exhibit more efficient hybridization with a complementary DNA sequence than the corresponding methylphosphonate analogs.

It has also been found that the phosphorothioate deoxynucleotides can be combined with normal deoxynucleotides in the same manner as a block copolymer in order to inhibit the proliferation of oncogenes. Alternatively, the phosphorothioate deoxynucleotides can be combined with normal deoxynucleotides in compounds analogous to graft copolymers, wherein the phosphorothioate derivatives are at either end of the chain, with the normal deoxynucleotides on the inside of the chain.

Thus, when R<sup>1</sup> signifies the phosphorothionate deoxynucleotide group and R<sup>2</sup> signifies the normal deoxynucleotide group, the compounds can for example, have the following formulas:



and



The compounds of the present invention have been found to inhibit HIV and HL-60 cell growth at rather low concentrations, approximately 1-20 micromoles in vitro. In vivo, it is preferred to attain a concentration of the active ingredient of from about 0.1 micromole to about 100 micromoles/cl in blood. This concentration can be achieved in a variety of dosage methods, which will be described hereinafter.

The method of Stec et al., in *J. Org. Chem.*, **50** (20):3908-3913 (1985), for automated synthesis of phosphorothioate oligodeoxynucleotides, provides a convenient method for synthesizing the desired compounds. Alternatively, Merigan et al., in U.S. Patent 3,687,808, discloses an alternate method for preparing the thioate esters. However, neither of these methods is efficient enough to permit routine synthesis of sufficient quantities of these compounds for genetic studies.

The oligodeoxynucleotides of the present invention have been found to inhibit expression of the integrated viral genome. The phosphorothioate oligodeoxynucleotides of the present invention have suitable chemical characteristics, namely, the ability to hybridize with complementary DNA/mRNA under physiological conditions, and better solubility properties relative to methylphosphonates. Moreover, the thioesters are as soluble in biological media as the parent compounds. Monitoring the <sup>31</sup>P NMR spectra of the ODN-1 sequence, both as unmodified and as a phosphorothioate analog, it was found that the unmodified oligodeoxynucleotide had a half-life of about 17 hours, whereas the phosphorothioate bonds were still intact after 10 days, within the accuracy of the <sup>31</sup>P NMR measurement (less than 5% decomposition based on the total signal intensity).

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a comparison of anti-HIV activity in three lengths of oligo-dC-S and oligo-dA-S.

Figure 2 shows the synergistic enhancement of antiviral activity of the combination of 2',3'-dideoxyadenosine and S-dC14.

Figure 3 shows the effect of S-AS on HL60 cell growth.

Figure 4 shows the effect of S-AS ODNs inhibition of DNA synthesis in HL60 cells.

Figure 5 shows the DNA sequence of coding exon of art/trs gene in HTLV-III BH10 and the sequences of oligodeoxynucleotides tested.

Figure 6 shows a detailed comparison of anti-HIV activity between 14-mer and 28-mer of S-dCn.

Figure 7 shows the effect of N-methylation of thymine on the antiviral activity of S-ODN-1.

Figure 8 shows the inhibition of de novo HIV DNA synthesis in ATH8 cells exposed to the virus by 28-mer of oligodeoxycytidine phosphorothioate.

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The normal oligodeoxynucleotides, methylphosphonate oligodeoxynucleotides, and phosphorothioate oligodeoxynucleotides can be synthesized by either the standard solution procedures or by modification of the procedure of Stec et al. in *J. Am. Chem. Soc.*, **106**, 6077-6089 (1984) using an automated synthesizer, such as an Applied Biosystems Inc., Model 380-B by the phosphoroamidite method.

Purification of the compounds was performed by reverse phase high performance liquid chromatography. The presence of P-S bonds in the phosphorothioates was shown using <sup>31</sup>P NMR spectroscopy. N3-methylthymidine was prepared and converted to the protected phosphoroamidite form and incorporated into the oligomer synthesis.

The phosphorothioates of the present invention can be synthesized in an Applied Biosystems 380-B DNA Synthesizer in a manner similar to that of the synthesis cycle for normal phosphate oligonucleotides using O-methylphosphoramidite. The major difference is in the reagents used during the oxidation step.

A 5% sulfur solution consisting of 7.5 grams of S<sub>8</sub> elemental sulfur, dissolved first in 71 ml carbon disulfide along with 71 ml pyridine and 7.5 ml triethylamine, is used as the oxidizing reagent. This reagent occupies bottle #13 on the 380B synthesizer. The total volume given is sufficient for a 3 column synthesis

of a 30 mer.

Before and after the oxidation step, the column is washed repeatedly with a 1:1 solution of carbon disulfide and pyridine in bottle #16 position to remove any residual sulfur which might precipitate in the lines. For a three column synthesis of a 30 mer, a total volume of 380 ml of this solution should be sufficient.

The solutions used must be as anhydrous as possible, and should be remade for each new synthesis.

The sulfur oxidation is not as rapid as the iodine oxidation, and thus requires a waiting step of 450 seconds during the synthesis cycle, as compared to 30 seconds for the iodine oxidation waiting step. Additionally, the end procedure is slightly altered in that the reverse flush is held five seconds longer than normal for a total of ten seconds to ensure the removal of any resulting salts dissolved in methanol after thiophenol is delivered to the column. Of course, variations are possible and will be apparent to those of ordinary skill in the art without more than routine experimentation.

Oligodeoxynucleotides with blocks of phosphorothioates at the 3' or 5' ends were synthesized by automatically changing the oxidation cycle at the required point. After cleavage from the column and deblocking in aqueous ammonia (60°, 10h), phosphorothioate oligomers and block copolymers were purified via reverse phase HPLC (PRP-1 column, 1% triethylammonium acetate buffer, pH 7-acetonitrile (20%, increase to 40% at 20 minutes), and the solution was extracted with two equal volumes of ethyl acetate, frozen in dry ice, and lyophilized. The solids were dissolved in 0.3 ml of 1M NaCl, and the product was precipitated by the addition of 3.5 volumes of absolute ethanol. The acetate salts of some phosphorothioate oligomers, particularly the homopolymer dC<sub>28</sub>, are extremely insoluble in 1 M NaCl. Introduction of a small amount of ammonia vapor, not aqueous ammonia, by a Pasteur pipette solubilized all the solids. The yield determined from absorbance at lambda max was about 30%.

The anti-sense sequence and the control sense and non-sense (same composition as anti-sense but in random sequence) are shown below:

Anti-sense: 5'-AAC GTT GAG GGG CAT

Non-sense: 5'-CTG AAG TGG CAT GAG

These compounds were purified using high performance liquid chromatography and precipitation by ethanol.

For the biological tests described below, a sequence (S-ODN-1), the phosphorothioate oligodeoxynucleotide, was selected which is an anti-sense counterpart to the nucleotide sequence existing in *tat-III* and *art/trs* genes of HIV, as these genes are essential for viral replication. This anti-sense oligodeoxynucleotide can block the expression of *tat-III* and *art/trs* genes. A sequence (S-ODN-2) was selected, which is complementary to the sequence at the initiation site of *tat-III*. Additional "random" sequences (S-ODN-5, oligo-dA, and oligo-dC) were also of interest. S-ODN-5, which does not exist in HIV either as an anti-sense or sense sequence, has the same content as dA, dG, dC, and dT residues and S-ODN-1, but is otherwise irrelevant to S-ODN-1. Oligo-dA and oligo-dC were used with 5, 14, and 28 nucleotide units to study the effects of chain length.

As defined herein, an anti-sense base sequence is a sequence complementary to the target genetic message which can serve to selectively suppress gene expression.

With regard to inhibition of cell proliferation, promyelocytic leukemia cells contain amplified copies of the *c-myc* gene, a gene that is representative of a class of genes known as oncogenes, i.e., cellular genes whose de-regulation is involved in tumorigenesis.

In the process according to the present invention, phosphorothioate oligodeoxynucleotide analogs of the same anti-sense sequence as previously described (i.e., complementary to the initiation codon of the *c-myc* gene) were found to inhibit proliferation of HL60 cells, cf. Figures 3 and 4.

It was found that only the anti-sense sequence provided significant inhibition of cell proliferation as measured by cell count, as shown in Figure 3, and 3H-thymidine incorporation as shown in Figure 4, as well as reduction of *c-myc* protein. The effects lasted for up to three days, using phosphorothioate oligodeoxynucleotide concentrations significantly lower (i.e., less than 1%) than those required for the normal oligomer to have any real effect.

Figure 3 shows anti-sense (top panel) and non-sense (bottom panel) sequences which were added on day 0 of cell culture to triplicate wells of a 96-well microtiter plate, and cell numbers were determined daily in all cultures. Anti-sense S-ODNs effectively inhibited growth at final concentrations between 0.5 and 10 microliters. While 0.1 micro molar concentrations of coanti-sense was effective, not all nonsense S-ODN concentrations affected cell proliferation.

To obtain the results shown in Figure 4, non-sense or antisense S-ODNs were added at a final concentration of 50 micromolar on day 0 to cells seeded at 3 x 10<sup>5</sup>/ml. DNA synthesis was determined on day 1 by incubating cells with 1 uCi <sup>3</sup>H-thymidine for 4 hours, after which time 10% trichloroacetic acid was

added and acid precipitable radioactivity was trapped on Whatman glass fiber filters. The filters were subjected to liquid scintillation counting to determine levels of radioactivity.

The effect has been reproduced three times, and none of the controls used, namely, the non-sense sequence, has shown similar activity. Thus, the inhibition of proliferation observed is unique to the specific ODN analog of the precise base sequence herein described. The use of this compound in vivo could result in the cessation of growth of a tumor whose proliferation is dependent on the presence of the c-myc gene. By extrapolation, the S-ODN's complementary to sequences of other oncogenes will inhibit the growth of tumors in which these oncogenes are expressed.

TABLE 1 contains a list of the compounds which were synthesized for the antiviral tests. Each of the compounds was given a trivial name for the convenience of discussion, and has the molecular structure indicated by the conventional nomenclature for polynucleotides, with the exception that each internucleotide linkage indicated by subscript "s" is an Rp, Sp-phosphorothioate, wherein the average sulfur content is greater than 95%, as judged by  $^{31}\text{P}$  NMR analysis.

It was found that longer oligos had more potent effects, and that oligo-dC phosphorothioate had more potency than oligo-dA phosphorothioate on the basis of molarity of the compounds. Therefore, the binding of the oligos to the relevant polynucleotide site(s) and/or the HIV reverse transcriptase (as primer) of the virus leads to protection against the cytopathic effects of HIV.

TABLE 1

## Representative Test Compounds

<u>Trivial Name</u>	<u>Sequence (5'-3') of Phosphorothioate Analogues of Oligodeoxyribonucleotides</u>
S-ODN-1	d-(T <sub>s</sub> C <sub>s</sub> G <sub>s</sub> T <sub>s</sub> C <sub>s</sub> G <sub>s</sub> C <sub>s</sub> T <sub>s</sub> G <sub>s</sub> T <sub>s</sub> C <sub>s</sub> T <sub>s</sub> C <sub>s</sub> C)
S-ODN-2	d-(G <sub>s</sub> G <sub>s</sub> A <sub>s</sub> G <sub>s</sub> A <sub>s</sub> C <sub>s</sub> A <sub>s</sub> G <sub>s</sub> C <sub>s</sub> G <sub>s</sub> A <sub>s</sub> C <sub>s</sub> G <sub>s</sub> A)
S-ODN-3	d-(C <sub>s</sub> A <sub>s</sub> T <sub>s</sub> A <sub>s</sub> G <sub>s</sub> G <sub>s</sub> A <sub>s</sub> G <sub>s</sub> A <sub>s</sub> T <sub>s</sub> G <sub>s</sub> C <sub>s</sub> C <sub>s</sub> T)
S-ODN-4	d-(C <sub>s</sub> T <sub>s</sub> G <sub>s</sub> G <sub>s</sub> T <sub>s</sub> T <sub>s</sub> C <sub>s</sub> G <sub>s</sub> T <sub>s</sub> C <sub>s</sub> T <sub>s</sub> C <sub>s</sub> C <sub>s</sub> C)
Oligo-dC	(dC) <sub>n</sub> n=5, 14, 28
Oligo-dA	(dA) <sub>n</sub> n=5, 14, 28

S-ODN (phosphorothioate analog-d) = oligodeoxynucleotides or phosphorothioates wherein dA and dC are compounds of Formula I.

Figure 1 shows a comparison of anti-HIV activity in three lengths of oligo-dC-S and oligo-dA-S. Oligo dC-phosphothioate 28 mer was found to inhibit viral replication and protect ATH8 cells from HIV to 100% at a concentration of 3 micromoles, cf. Figure 1 and Table 1. The target cells (2 x 10<sup>5</sup> ATH8 cells) in each tube were pre-treated with the stated concentration of each oligomer for 16 hours and then incubated with Polybrene for 45 minutes. After centrifugation, each set of pelleted cells was exposed to HIV (500 virions per cell, which is a much higher dose than the minimal cytopathic dose) and incubated for one hour. Complete media (2 ml RPMI1640) supplemented with L-glutamine (4 mM), 2-mercaptoethanol (5 x 10<sup>-2</sup>M), penicillin (50 unit/ml), and streptomycin (50 micrograms/ml), and containing 15% fetal calf serum and IL-2 (15% of conventional IL-2 from Advanced Biotechnologies, Inc., Silver Spring, MD, plus 20 unit/ml of recombinant IL-2 from Amgen Biochemicals, Thousand Oaks, CA) with the various concentrations of oligomers added. The number of viable cells were counted in a hemocytometer using the trypan blue exclusion method for day 7 following exposure to the virus. Filled columns represent non-virus exposed cells, and open columns represent virus exposed cells. The inhibitory effects of S-dC<sub>n</sub> are greater and more persistent than those of S-dA<sub>n</sub> for 14-mer and 28-mer. The longer sequences were found to be more effective than the shorter ones.

There are several possible mechanisms of the antiviral activity of the oligos, such as the inhibition of reverse transcriptase or direct effects against viral particles. Experiments using an assay for reverse transcriptase activity did not show significant inhibition of the enzyme activity.

The phosphorothioates of the present invention can be used with any pharmaceutically acceptable carriers such as, for example, water, saline solution, human blood, and other acceptable carriers.

HIV Culture with Oligodeoxynucleotides

The HIV cytopathic effect inhibition with oligodeoxynucleotides was performed with 18 hours of pretreatment of  $2 \times 10^5$  target cells (ATH8 cells) with oligos prior to exposure to HTLV-III<sub>B</sub>. After this pretreatment, target cells were treated with Polybrene (2 micrograms/ml) for one hour. The target cells were then, respectively, exposed to HTLV-III<sub>B</sub> virus (generally 500 virions per cell in this series of experiments) for one hour. The  $2 \times 10^5$  cells were then diluted to 2 ml with complete media containing IL-2 and various concentrations of oligos.

The number of viable cells was counted in a hemocytometer using the trypan blue exclusion method on day 7 following exposure to the virus. Each set of data was obtained from simultaneously performed experiments so as to make a precise comparison among agents tested.

Determination of HIV gag Protein Expression

The percentage of cells expressing p24 gag protein of HIV was determined by indirect immunofluorescence microscopy by using anti-HIV p24 murine monoclonal antibody.

Southern Blot Analysis

Target cells ( $1 \times 10^7$  ATH8 cells) were pretreated with or without S-dC28 at various concentrations for sixteen hours, then treated with Polybrene, exposed to HIV (500 virus particles per cell), resuspended, and cultured in the presence or absence of S-dC28. On days 4 and 7 following the exposure to the virus, high molecular weight DNA was extracted, digested with Asp718 (a Kpn I isoschizomer from Boehringer-Mannheim, Indianapolis, IN), and subjected to Southern blot analysis hybridized with a labelled insert of molecular clone of the env region of HTLV-III (BH10) containing a 1.3 Kb Bgl II fragment.

The results of the antiviral effect and cytotoxicity of ODNs are shown in Table 2. The two n-ODNs and one M-ODN tested showed no significant inhibitory effects, while all the S-ODNs exhibited significant inhibition of the cytopathic effect of HIV. Surprisingly, the 14-mer phosphorothioate homo-oligomer of dC(S-dC14) was found to be the most potent antiviral compound among those tested in this series of experiments. Since phosphorothioate ODNs which are not anti-sense sequences appear to be very effective antiviral agents, an attempt was made to clarify the nature of the base composition effect. Comparing the effects of 5 micromoles of each of the 14-mer phosphorothioates tested, it was found that inhibition of the viral cytopathic effect was approximately linear with respect to the G + C content of the analog (cf. data from Table 2).

TABLE 2

COMPOUND	ANTI-VIRAL EFFECT (%)				CYTOTOXICITY (%)			
	1	5	10	25 (uM)	1	5	10	25 (uM)
S-ODN-1	0	43	72	95	0	0	0	20
n-ODN-1	3	2	9	4	35	22	27	14
M-ODN-1	8	20	13	10	20	27	20	20
S-ODN-2	11	56	100	78	0	0	0	6
n-ODN-2	11	9	0	11	18	28	35	32
S-ODN-3	0	6	44	94	0	0	0	13
S-ODN-4	0	53	78	100	0	0	0	0
S-dC14	25	100	100	100	0	0	0	0

Comparison of Anti-HIV Activity in Various Lengths of Oligo-dC and Oligo-dA Phosphorothioates

Because it is possible that inter-assay variation may create an inappropriate comparison of antiviral activity among agents, experiments were performed simultaneously to make more precise comparisons.

5 In the comparison in Figure 6 of the anti-HIV activity between the 14-mer and the 28-mer (cf. Figure 1), it was found that there is obvious length effect even with an increase of several nucleotide lengths as short as three nucleotides.

As illustrated in Figure 1, the inhibitory effects of S-dCn are greater and more persistent than those of S-dAn for both 14-mer and 28-mer, while 5-mers belonging to both categories failed to inhibit the cytopathic effect of the virus significantly. The order of effectiveness of the homo-oligomers was dC>dT≥dA for 14-mer. It was found that the longer sequences were more effective than the shorter sequences at the same molar concentration of nucleotide units. For example, as shown in Figure 6, the 28-mer S-dC28 at concentrations as low as 0.5 Micromoles (13.5 micromoles of nucleotide equivalents) gave complete protection against the virus, while the corresponding 14-mer at 5 micromoles (65 micromole equivalents) had only a moderate effect. The S-dC28 gave the most consistent and durable antiviral effects under the conditions used in these experiments. These data suggest a real length effect, and argue against either metal ion chelation or degradation to reactive monomers.

Effect of N3-methyl-thymidine Substitution in ODN Analog on Anti-HIV Activity

20 Shown in Figure 5 is N-Me-ODN-1 of N3-methyl-thymidine-containing anti-sense oligodeoxynucleotide, which has a methylated thymidine at positions 4 and 9. Random sequence ODN-4 has the same base content as ODN-1, but has less than 70% homology with any sequence in HTLV-III BH10 genomic sequence as anti-sense or as sense. The homo-oligomers of dC and dA were synthesized in three lengths, where n was 5, 14, and 28.

25 N3-methyl-thymidine-containing S-ODN-1 showed no anti-HIV activity, while S-ODN-1 consistently exhibited substantial activity against HIV, as shown in Figure 7. Since N3-substitution on the pyrimidine base is known to reduce hydrogen bonding profoundly to complementary adenosine residues, the relative inactivity of this N3-methyl-thymine-containing analog of phosphorothioate suggests that antiviral activity could be brought about by binding to nucleotide sequences at least one mechanism.

Inhibition of de novo HIV DNA Synthesis in ATH8 Cells Exposed to the Virus by 28-mer of Oligodeoxycytidine Phosphorothioate

35 Figure 8 shows the inhibitor effect of the phosphorothioate oligodeoxycytidine analog (S-dC28) on de novo HIV DNA synthesis in target cells. On days 4 and 7 following the exposure to the virus, a substantial amount of viral DNA was detected by Southern blot analysis without antiviral agents. S-dC28, as well as 2',3'-dideoxyadenosine as the positive control, significantly inhibited the de novo synthesis of viral DNA at concentrations as low as 1 micromolar.

40 On day 4, shown in lanes A-E, and day 7, shown in lanes F-J, following exposure to the virus, high molecular weight DNA was extracted. Lanes A and F contain DNA from ATH8 cells that were exposed to the virus and not protected by S-dC28. Lanes B and G, C and H, D and I, contain DNA from ATH8 cells pretreated and cultured with 1 micromole, 5 micromoles, and 7 micromoles S-dC28, respectively. Lanes E and J contain DNA from ATH8 cells treated with 50 micromoles 2',3'-dideoxyadenosine, and lane K contains DNA from ATH8 cells that was not exposed to the virus. The 2.7 Kb env-containing internal KPN I fragment of the virus genome was detected only in lanes A and F.

Failure to Inhibit the Expression of Viral Protein by 28-mer Oligodeoxycytidine Phosphorothioate (S-dC28) in Chronically HIV Infected Cells

50 As illustrated in Table 3, S-dC28 failed to reduce gag protein positivity of target cells assessed by indirect immunofluorescent assay in chronically HIV-infected H9 cells at concentrations as high as 25 micromoles for the duration of the experiment, 120 hours.

55

TABLE 3

Percentage of <u>gaq</u> positive cells				
<u>S-dC28</u>	8	24	72	120
(hours in Culture with Compound)				
0 micro M	79	90	70	78
5 micro M	82	91	85	79
10 micro M	74	80	71	82
25 micro M	69	86	75	74

Synergistic Enhancement of Antiviral Activity of 2',3'-Dideoxyadenosine by 14-mer Oligodeoxycytidine Phosphorothioate

It is emphasized that the various dideoxynucleosides, including azidothymidine (AZT), dideoxycytidine, and dideoxyadenosine, require anabolic phosphorylation within target cells to become active anti-retroviral agents. The mechanisms of action appear to be competitive inhibition of reverse transcriptase and/or termination of nascent DNA chain formation.

Figure 2 shows the effect of the combination of 2',3'-dideoxyadenosine and S-dC14. Synergistic effects were obtained with a combination of S-dC28 or S-dC14 and a dideoxynucleoside. The target cells ( $2 \times 10^5$  ATH8 cells per tube) were preincubated with the stated concentrations of S-dC14 for 24 hours and pretreated with 2 micrograms/ml of Polybrene for 45 minutes. After centrifugation, pelleted cells were exposed to the HIV (1000 virions per cell) for one hour. The cells were incubated in 2 ml of complete media containing IL-2, and the viable cells were counted on day 13.

The oligomers of the present invention are likely to work by different mechanisms and would not be expected to require anabolic phosphorylation. However, as shown in Figure 2, the combination of 2',3'-dideoxyadenosine and 14-mer oligodeoxycytidine phosphorothioate gave a marked synergistic enhancement of antiviral activity. For example, 2 micromoles of dideoxyadenosine showed complete protection of target cells against the viral cytopathic effect with 5 micromoles S-dC14, while each of the two agents alone showed only marginal protective effects in this experiment.

For the enhancement of antiviral activity shown in Figure 2, the target cells were pretreated with various concentrations of S-dC14 for sixteen hours, and then pretreated with 2 micrograms/ml polybrene, exposed to 1000 virus particles per cell for one hour, resuspended in 2ml complete media containing IL-2 with or without various concentrations of 2',3'-dideoxyadenosine. On day 13 after the exposure to the virus, viable cells were counted by the trypan blue dye exclusion method. These experiments involved a more potent viral inoculum for a longer duration than in the other experiments described herein.

As shown in Table 2, only phosphorothioate analogs showed anti-HIV activity. Thus, it is believed that it is mainly the relative resistance of the phosphorothioate analogs to nucleases that preserves them relative to n-ODNs, and allows them to reach and remain at their target site. This was supported in relation to the media used in the in vitro test system by following the  $^{31}\text{P}$  NMR spectra of the n-ODN-1 and S-ODN-1 compounds as a function of time. Breakdown of the normal oligodeoxynucleotide was seen from the buildup of the terminal phosphate peak, indicating a half-life of about seventeen hours under these conditions, while the S-analogs exhibited no significant degradation even after a week, within the greater than 5% accuracy of the method.

Similarly, samples of solution of S-ODNs taken from the in vitro cytopathic assay and incubated in human serum at  $37^\circ\text{C}$  showed no degradation after seven days. The inactivity of a methylphosphonate analog (M-ODN-1) in the cytopathic inhibition assay could have been due to its poor ability to hybridize strongly to the target sequence.

The potency of anti-HIV activity of S-dC28, one of the most potent analogs tested, is almost comparable to that of 2',3'-dideoxycytidine on the basis of molarity, i.e. both agents showed complete antiviral activity at 0.5 micromoles in the present assay system, as well as in terms of therapeutic index, the

ratio of cytotoxic concentration relative to effective concentration. S-dC28 generally shows a comparable in vitro index to those of dideoxycytidine and dideoxyadenosine.

Generally, it has been assumed that anti-sense sequences inhibit the expression of various genes by translation arrest, i.e. that they bind to mRNA and block its translation. In order to test this possibility, gag protein synthesis was analyzed in chronically HIV-infected and -producing H9 cells by indirect immunofluorescent assay under a microscope. S-dC28 did not inhibit gag protein positivity in H9/HTLV-IIIb cells at concentrations as high as 25 micromoles, as shown in Table 3. Although gag positivity of cells is only a partially quantitative parameter for protein production, this result suggests that the potent anti-HIV activity of S-dC28 at concentrations as low as 0.5 micromoles might not be from a translation arrest per se. Alternatively, the level of any translation arrest could have been below the threshold of detection by indirect immunofluorescent assay under a microscope. By contrast, a Southern blot analysis used to explore de novo synthesis of HIV DNA in target cells showed complete inhibition by S-dC28 at concentrations down to 1 micromole. Therefore, one mechanism for the antiviral effect could depend on blocking viral replication perhaps prior to, or at the stage of, pro-viral DNA synthesis.

The possibility that the S-ODN analogs may interfere with HIV binding to target cells was tested. The T4 molecule on the cell surface is known to be the main receptor for HIV in T4+ cells. No inhibition by S-dC28 was observed in experiments using radiolabelled virus for specific binding of the labelled virus to the T4 molecule in T4 cells (H9 cells), thus suggesting that inhibition of viral binding to the cell surface is not responsible for the activity. In addition, no detectable changes in the T4, HLA-DR, T8, T3, or Tac antigen on the cell surface of ATH8 cells were shown by fluorescent-activated cytofluorometry after sixteen hours of incubation with 1 micromole S-dC28. Overall, these findings, including a base composition effect and a length effect, suggest that the antiviral activity is mediated by inhibition of HIV pro-viral DNA synthesis, perhaps brought about, at least in part, by binding of the S-ODNs to a viral nucleotide sequence.

Another mechanism which should be considered is induction of interferon production such as that proposed for phosphorothioate analogs of poly-r(I-C). No induction of gamma-interferon was observed in the supernatant of the culture with S-dC14, and 1000 units of recombinant alpha- or gamma-interferon added directly to the cultures did not inhibit the cytopathic effect in the assay systems. Also, since there are no data to support the concept that phosphorothioate internucleotide linkages have a thiol character, and can thus form disulfides, the mechanism of action would likely be different from that proposed for antiviral polynucleotides having thiolated bases such as 5-mercapto-cytosine or -uracil.

Phosphatase-resistant <sup>35</sup>S-phosphorothioate end-labelled S-dC28 was employed to investigate the permeability of target cells. Significant increases of radioactivity in ATH8 and H9 cells were observed within several minutes, thus supporting the uptake of these compounds by the cells.

S-ODNs also showed substantial inhibition of purified HIV reverse transcriptase activity in the in vitro experiment using a viral DNA (3'-orf) inserted in an M-13 vector as a template with a universal primer. Under some conditions, it was found that phosphorothioate analogs can serve as competitive inhibitors of template-primer, and that this class of compounds appears to have multiple mechanisms of action. The precise mechanism, however, including non-sequence specificity of the anti-viral activity, direct inhibition of the viral DNA polymerase or additional translation arrest at high concentration for complementary sequences, requires further research at this time.

After a number of days in culture, generally 7-10 days, either substantial cell death due to HIV infection (HIV cytopathic effect) or the protective effect of oligos against the cytopathicity of HIV was observed.

In other experiments, the target cells (ATH8 cells) appeared to be protected against HIV by phosphorothioate oligos (S-ODN-1, 2, and 4), but not by unmodified oligos which have the same sequences. Moreover, in the same experiment, "random" sequences of phosphorothioate, such as the 14-mer oligo-dC and S-ODN-5, showed substantial protection against HIV cytopathic effect. The protective effects of the phosphorothioate oligos brought about by binding to relevant polynucleotide sites for infection and cytopathic effects of the virus were also investigated, as well as various lengths of oligo-dC and oligo-dA phosphorothioates (5, 14, and 28 mers) in the cytopathic effect assay. Bio testing is described in Mitsuya et al., PNAS, 83: 1911-1915 (1986).

With respect to inhibition of tumor growth, the effects of the all-phosphoro oligomers are quite different from the effects of the all-phosphothioated oligomers. Additionally, combined mixtures of chemically combined copolymers of the oligomers of the present invention can be used to inhibit proliferation of tumor cells.

These copolymers can assume a variety of configurations, for example, an end-capped polymer with two phosphothioated oligomers at each end of a 14-mer polymer. Alternatively, block copolymers can be provided, such as polymers with repeating blocks such as nine phosphonate, nine phosphothioated, and nine phosphonated mers in a 28-mer polymer which has 27 internucleotide phosphate bonds, or singly

alternating copolymers. Many of these copolymers have intermediate properties.

It has been found that the normal oligomers are cleaved after about seventeen hours in serum, but that in the cell, the half-life of these compounds may be as long as several days. The use of the phosphorothionated derivatives lengthens the lifespan of the active compounds, which provides these compounds more time in which to inhibit the expression of the oncogenes.

Initial physico-chemical studies indicate that the end-capped compounds are quite resistant to nucleases, by a factor of about 100, but hybridize almost as well as the normal phosphonated compounds, as indicated by their melting temperatures, as shown in Table 4, below.

TABLE 4

## Melting Temperature of Oligomers\*

15	<u>With Poly-rA:</u>	O-dT7	10°C	
		O-dT14	39	S-dT14 20°C
		O-dT21	48	
		O-dT28	52	S-dT28 36
20		S-dT15	23	
		2S-3',5' cap-dT15	37	
		4S-3',5' cap-dT21	43	
25		5S-3',5' cap-dT23	44	
	<u>Homo-duplexes:</u>	S-dT14 + O-dA14	21	
		S-dT28 + O-dA28	39	
30		O-dT14 + O-dA14	38	
		S-dT28 + S-dA28	32	
<u>LAS1 dGGGAAGGATGGCGACGCTG (70%G/C):</u>				
35		S-sense+S-antisense	56	
		S-sense+O-antisense	65	
		O-sense+O-antisense	75	

\*Determined by UV melting at 260 nm.

NOTE: S-dA/T Tms are quite low, but S-dC/G are relatively high.

Several oligodeoxynucleotides were studied with regard to DNase sensitivity, cf. Table 5. These include cytidine homopolymers, ODN-4 (an anti-message 28-mer complementary to the 3' region of the *art/trs* region of HIV BH10 clone), and myc-1 (a 15-mer complementary to the initiation codon region of the *C-myc* oncogene). The DNases employed were predominantly endonuclease S1, the *exo-* and endonuclease P1, and snake venom (SV) phosphodiesterase. The concentration of S1 nuclease was ten-fold higher (100 micromoles/ml) for reactions of oligo-dC, since both the normal and PS analog were degraded extremely slowly by this enzyme. S1 and P1 nuclease digestion proceeded 2-45 times more slowly for the S-ODNs than for the normal oligomers, with the 150-mer being somewhat more readily digested than the 28-mer. The 2S-capped myc-1 species behaved similarly to the all-PS compounds.

The S-ODNs are all but impervious to the effects of SV phosphodiesterase, and in this case the differences from normal oligos are quite dramatic. For the homopolymers, a half-life of  $>10^5$  seconds was determined, which represents a three-log decrease of the rate versus the normal oligomer. Similar results were found with myc-1 and ODN-4. Digestion of 2S-cap-myc-1 by SV phosphodiesterase was also slowed, as shown in Table 5, but not as markedly as some of the other species. However, the half-life of 3',5'-2S-cap-myc-1 in 50% human serum, as measured by  $^{31}\text{P}$  NMR, is greater than one month versus two to three

days for normal myc-1.

TABLE 5

Nuclease Susceptibilities of Oligomers, $t_{1/2}$ (sec) <sup>1</sup>						
O-dC <sub>15</sub>	822		1810		35	
S-dC <sub>15</sub>	11000	134	27700	15.3	133000	3800
O-dC <sub>28</sub>	3910		3160		70	
S-dC <sub>28</sub>	7990	2	48600	15	>100000	>1400
O-ODN-4	203		72		20	
S-ODN-4	8370	41	1370	19	92500	4625
O-myc-1	36		69		28	
S-myc-1	330	9	249	4	12400	443
myc-1-cap	1530	43	807	12	4230	151

<sup>1</sup>Ratio =  $t_{1/2}$ PS-oligo/ $t_{1/2}$ PO-oligo

ODN-4 = d-TCGTCGCTGTCTCCGCTTCTTCCTGCCA

myc-1 = d-AACGTTGAGGGGCAT

25

As described previously, the preferred dosage of the compounds of the present invention is that which is necessary to attain a concentration in blood of from about 0.1 to about 100 micromoles/cl. This concentration can be achieved in a variety of ways.

Pharmaceutical compositions within the scope of the present invention include compositions wherein the active ingredient thereof is contained in an effective amount to achieve its intended purpose. A preferred range has been described above, and determination of the most effective amounts for treatment of each type of tumor or virus is within the skill of the art.

In addition to the phosphothioated compounds of the present invention, these pharmaceutical compositions may contain suitable excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Preferably, the preparations, particularly those which can be administered orally and which can be used for the preferred type of administration, such as tablets, dragees, and capsules, and preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration parenterally or orally, and compositions which can be administered buccally or sublingually, including inclusion compounds, contain from about 0.1 to about 99 percent by weight of active ingredients, together with the excipient.

The pharmaceutical preparations of the present invention are manufactured in a manner which is itself well known in the art. For example, the pharmaceutical preparations may be made by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. The process to be used will depend ultimately on the physical properties of the active ingredient used.

Suitable excipients are, in particular, fillers such as sugars, for example, lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch, paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added, such as the above-mentioned starches as well as carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are flow-regulating agents and lubricants, for example, such as silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores may be provided with suitable coatings which, if desired, may be resistant to gastric juices. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate, are used. Dyestuffs and pigments may be

added to the tablets of dragee coatings, for example, for identification or in order to characterize different combinations of active compound doses.

Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.


Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of the active compounds with a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols, or higher alkanols. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.

Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble or water-dispersible form. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.

Additionally, the compounds of the present invention may also be administered encapsulated in liposomes, pharmaceutical compositions wherein the active ingredient is contained either dispersed or variously present in corpuscles consisting of aqueous concentric layers adherent to lipidic layers. The active ingredient, depending upon its solubility, may be present both in the aqueous layer and in the lipidic layer, or in what is generally termed a liposomic suspension. The hydrophobic layer, generally but not exclusively, comprises phospholipids such as lecithin and sphingomyelin, steroids such as cholesterol, more or less ionic surfactants such as dicetylphosphate, stearylamine, or phosphatidic acid, and/or other materials of a hydrophobic nature. The diameters of the liposomes generally range from about 15 nm to about 5 microns.


### Claims

1. A pharmaceutical composition comprising a phosphorothioate oligodeoxynucleotide disposed in a pharmaceutically acceptable carrier for use in the prevention of disease caused by replication of foreign nucleic acids in the presence of normal living cells.
2. A pharmaceutical composition according to claim 1 wherein the disease is caused by HTLV-III.
3. A pharmaceutical compound for the prevention of disease caused by replication of foreign nucleic acids in the presence of normal living cells; of the Formula (I):




20 wherein  $n$  is an integer from 5 to 30,  $B$  is selected from adenine (A), guanine (G), cytosine (C) and thymidine (T), and  $X$  is selected from S and O, with the proviso that at least one  $X$  in the compound is S, such that said compound of Formula I is an antisense sequence.

- 25
4. A pharmaceutical compound of claim 3 wherein the disease is caused by HTLV-III.
5. The compound of either of claims 3 or 4, wherein either in two monomers  $X$  is S and in the remaining monomers  $X$  is O;  
or wherein the polymer is end-capped with monomers wherein  $X$  is S and in the remaining monomers  $X$  is O;  
30 or wherein the monomers wherein  $X$  is S and the monomers wherein  $X$  is O are present in equal amounts.
6. The compound of any of claims 3 or 5, wherein  $n$  is in the range of 14 to 30 inclusive.
- 35 7. The compound according to either of claims 3 or 4, wherein greater than 95% of  $X$  are S.
8. A compound according to claim 7, wherein  $X$  is S.
9. A pharmaceutical composition comprising a compound for the inhibition of HTLV-III of Formula II:
- 40



wherein n is an integer from 5 to 30, and B is selected from adenine (A) guanine (G), cytosine (C) or thymidine (T).


10. The composition according to Claim 9 wherein the oligodeoxyribonucleotide is oligo-dC-phosphorothioate having from about 5 mers to about 30 mers.
11. The composition according to Claim 9 wherein the oligodeoxynucleotide is oligo-dA phosphorothioate having from about 5 mers to about 30 mers.
12. The composition according to Claim 9 wherein the oligodeoxynucleotide is oligo-dA phosphorothioate of about 28 mers.
13. The composition according to any of claims 9 to 12 wherein the carrier is selected from saline, an organic carrier, or blood.
14. The composition according to claim 9, wherein the dideoxynucleotide is 2',3'-dideoxyadenosine.
15. A method for preventing replication and cytopathic effects of foreign nucleic acid in cells in vitro, comprising exposing the cells to a replication-inhibiting amount of an oligodeoxynucleotide of the Formula II of Claim 9.
16. A method for preventing replication of foreign nucleic acid in normal living cells in vitro, comprising exposing the cells to a replication-inhibiting amount of an oligodeoxynucleotide of Formula I of Claim 3 wherein the oligodeoxynucleotide has a base sequence complementary to a base sequence of human immunodeficiency virus (HIV).
17. A pharmaceutical composition comprising a compound of Formula I of Claim 3 and a dideoxynucleotide.
18. The use in the manufacture of a medicament for the treatment of disease caused by expression of a foreign nucleic acid such as an oncogene or HTLV-III, said medicament comprising a composition comprising a compound of the Formula I:



wherein n is an integer of from 5 to 30, B is selected from adenine (A), guanine (G), cytosine (C) and thymine (T), and X is selected from S and O, with the proviso that at least one X in the compound is S, to provide a specific "anti-sense" sequence to portion of said foreign nucleic acid.

19. The use according to claim 18 wherein the disease is caused by HTLV-III.


20. The use of either of claims 18 or 19, wherein in two monomers X is S and in the remaining monomers X is O.
21. The use of claim 20, wherein the polymer is end-capped with monomers wherein X is S and in the remaining monomers X is O.
22. The use of either of claims 18 or 19, wherein the monomers wherein X is S and the monomers wherein X is O are present in equal amounts.
23. The use of claim 18, wherein the oncogene is a C-myc gene.
24. The use in the manufacture of a composition for the prevention of disease caused by replication of foreign nucleic acids in the presence of normal living cells, comprising phosphorothioate oligodeoxynucleotide in a pharmaceutically acceptable carrier.
25. The use according to claim 24, wherein the disease is caused by HTLV-III.
26. The use according to claim 24 or 25, wherein the phosphorothioate oligodeoxynucleotide has the Formula II.



- wherein n is an integer of from 2 to 30 and B is selected from adenine (A) guanine (G), cytosine (C) and thymine (T).
27. The use according to claim 26, wherein the oligodeoxynucleotide is oligo-dC phosphorothioate having from about 5 mers to about 30 mers.
28. The use according to claim 26, wherein the oligodeoxynucleotide is oligo-dA phosphorothioate having about 5 mers to about 30 mers.
29. The use according to claim 26, wherein the oligodeoxynucleotide is oligo-dA phosphorothioate of about 28 mers.
30. The use according to claim 26, wherein the pharmaceutically acceptable carrier is selected from saline, an organic carrier, or blood.
31. The use according to claim 26, wherein the dideoxynucleotide is 2', 3'-dideoxyadenosine.


# Patentansprüche

1. Pharmazeutische Zusammensetzung, die ein in einem pharmazeutisch annehmbaren Träger vorliegendes Phosphorthioat-Oligodesoxynucleotid enthält, zur Verwendung bei der Verhinderung von durch Replikation fremder Nukleinsäuren in Anwesenheit normaler lebender Zellen verursachter Krankheit.
2. Pharmazeutische Zusammensetzung nach Anspruch 1, wobei die Krankheit durch HTLV-III verursacht wird.
3. Pharmazeutische Verbindung zur Verhinderung von durch Replikation fremder Nukleinsäuren in Anwesenheit normaler lebender Zellen verursachter Krankheit, mit der Formel (I):




wobei n eine ganze Zahl von 5 bis 30 ist, B aus Adenin (A), Guanin (G), Cytosin (C) und Thymin (T) ausgewählt ist, und X aus S und O ausgewählt ist, mit der Maßgabe, daß mindestens ein X in der Verbindung S ist, so daß die Verbindung der Formel I eine Antisinn-Folge darstellt.

4. Pharmazeutische Verbindung nach Anspruch 3, wobei die Krankheit durch HTLV-III verursacht wird.
5. Verbindung nach Anspruch 3 oder 4, wobei entweder in zwei Monomeren X jeweils S und in den übrigen Monomeren X jeweils O ist, oder wobei der Polymer Endstrukturen in Form von Monomeren hat, bei welchen X als S vorliegt und wobei in den übrigen Monomeren X als O vorliegt, oder wobei die Monomere, bei denen X jeweils S ist, und die Monomere, bei denen X jeweils O ist, in gleichen Mengen vorhanden sind.
6. Verbindung nach einem der Ansprüche 3 bis 5, wobei n im Bereich von 14 bis 30 einschließlich liegt.
7. Verbindung nach Anspruch 3 oder 4, wobei mehr als 95% von X als S vorliegen.
8. Verbindung nach Anspruch 7, wobei X jeweils S ist.
9. Pharmazeutische Zusammensetzung, die eine Verbindung zur Unterdrückung von HTLV-III der Formel II enthält:



- 20 wobei n eine ganze Zahl von 5 bis 30 ist, und B aus Adenin (A), Guanin (G), Cytosin (C) oder Thymidin (D) ausgewählt ist.
- 25 10. Zusammensetzung nach Anspruch 9, wobei das Oligodesoxyribonucleotid ein Oligo-dC-Phosphorthioat mit etwa 5 bis 30 Meren ist.
11. Zusammensetzung nach Anspruch 9, wobei das Oligodesoxynucleotid ein Oligo-dA-Phosphorthioat mit etwa 5 bis 30 Meren ist.
12. Zusammensetzung nach Anspruch 9, wobei das Oligodesoxynucleotid ein Oligo-dA-Phosphorthioat mit etwa 28 Meren ist.
13. Zusammensetzung nach einem der Ansprüche 9 bis 12, wobei der Träger aus physiologischer Kochsalzlösung, einem organischen Träger oder Blut ausgewählt ist.
- 35 14. Zusammensetzung nach Anspruch 9, wobei das Didesoxynucleotid ein 2',3'-Didesoxyadenosin ist.
15. Verfahren zur Verhinderung der Replikation und zytopathischer Effekte fremder Nukleinsäure in Zellen in Vitro, wobei die Zellen einer replikationsunterdrückenden Menge eines Oligodesoxynucleotids der Formel II nach Anspruch 9 ausgesetzt werden.
- 40 16. Verfahren zur Verhinderung der Replikation fremder Nukleinsäure in normalen lebenden Zellen in Vitro, wobei die Zellen einer replikationsunterdrückenden Menge eines Oligodesoxynucleotids der Formel I nach Anspruch 3 ausgesetzt werden, wobei das Oligodesoxynucleotid eine zu einer Basensequenz des Humanimmundefektvirus (HTLV) komplementäre Basensequenz hat.
- 45 17. Pharmazeutische Zusammensetzung, die eine Verbindung der Formel I nach Anspruch 3 und ein Didesoxynucleotid enthält.
- 50 18. Verwendung bei der Herstellung eines Medikaments zur Behandlung von durch Expression einer fremden Nukleinsäure wie beispielsweise eines Onkogens oder HTLV-III verursachter Krankheit, wobei das Medikament eine Zusammensetzung mit einer Verbindung der Formel I enthält:



20 wobei n eine ganze Zahl von 5 bis 30 ist, B aus Adenin (A), Guanin (G), Cytosin (C) und Thymin (T) ist, und X aus S und O ausgewählt ist, mit der Maßgabe, daß mindestens ein X in der Verbindung S ist, um eine spezifische "Antisinn"-Sequenz zu einem Teil der fremden Nucleinsäure zu schaffen.

25 19. Verwendung nach Anspruch 18, wobei die Krankheit durch HTLV-III verursacht wird.

20. Verwendung nach Anspruch 18 oder 19, wobei in zwei Monomeren X jeweils S ist und in den übrigen Monomeren X jeweils O ist.

30 21. Verwendung nach Anspruch 20, wobei das Polymer als Endstrukturen Monomere aufweist, bei denen X jeweils S ist, und wobei in den übrigen Monomeren X jeweils O ist.

22. Verwendung nach Anspruch 18 oder 19, wobei die Monomere, bei denen X jeweils S ist, und die Monomere, bei denen X jeweils O ist, in gleichen Mengen vorhanden sind.

35 23. Verwendung nach Anspruch 18, wobei das Onkogen ein C-Myc-Gen ist.

24. Verwendung bei der Herstellung einer Zusammensetzung zur Verhinderung von durch Replikation fremder Nukleinsäuren in Anwesenheit normaler lebender Zellen verursachter Krankheit, die Phosphorothioat-Oligodesoxynucleotid in einem pharmazeutisch annehmbaren Träger enthält.


40 25. Verwendung nach Anspruch 24, wobei die Krankheit durch HTLV-III verursacht wird.

26. Verwendung nach Anspruch 24 oder 25, wobei das Phosphorothioat-Oligodesoxynucleotid die Formel II hat:

45

50

55




wobei n eine ganze Zahl von 2 bis 30 ist und B aus Adenin (A), Guanin (G), Cytosin (C) und Thymin (T) ausgewählt ist.

27. Verwendung nach Anspruch 26, wobei das Oligodesoxynucleotid ein Oligo-dC-Phosphorthioat mit etwa 5 bis 30 Meren ist.
28. Verwendung nach Anspruch 26, wobei das Oligodesoxynucleotid ein Oligo-dA-Phosphorthioat mit etwa 5 bis 30 Meren ist.
29. Verwendung nach Anspruch 26, wobei das Oligodesoxynucleotid ein Oligo-dA-Phosphorthioat mit etwa 28 Meren ist.
30. Verwendung nach Anspruch 26, wobei der pharmazeutisch annehmbare Träger aus physiologischer Kochsalzlösung, einem organischen Träger oder Blut ausgewählt ist.
31. Verwendung nach Anspruch 26, wobei das Didesoxynucleotid ein 2', 3'-Didesoxyadenosin ist.


# Revendications

1. Composition pharmaceutique comprenant un oligodésoxynucléotide phosphorothioate placé dans un support pharmaceutiquement acceptable, destinée à être utilisée dans la prévention de maladies causées par la réplication d'acides nucléiques étrangers en présence de cellules normales vivantes.
2. Composition pharmaceutique selon la revendication 1, selon laquelle la maladie est causée par le HTLV-III.
3. Composé pharmaceutique pour la prévention de maladies causées par la réplication d'acides nucléiques étrangers en présence de cellules vivantes normales, répondant à la formule (I) :



20 dans laquelle  $n$  est un nombre entier compris entre 5 et 30,  $\text{B}$  est choisi parmi l'adénine (A), la guanine (G), la cytosine (C) et la thymidine (T), et  $\text{X}$  est choisi parmi le S et l'O, à la condition qu'au moins un  $\text{X}$  dans le composé soit le S, de manière que ledit composé de formule I soit une séquence anti-sens.

- 25 4. Composé pharmaceutique selon la revendication 3 pour laquelle la maladie est causée par le HTLV-III.
5. Composé selon l'une quelconque des revendications 3 et 4, pour lequel soit dans deux monomères  $\text{X}$  est le S et dans les monomères restants  $\text{X}$  est l'O ;  
 soit le polymère est coiffé à son extrémité par des monomères dans lesquels  $\text{X}$  est le S et dans les monomères restants  $\text{X}$  est l'O ;  
 30 soit les monomères dans lesquels  $\text{X}$  est le S, et les monomères dans lesquels  $\text{X}$  est l'O sont présents en quantités égales.
6. Composé selon l'une quelconque des revendications 3 à 5 pour lequel  $n$  varie de 14 à 30.
- 35 7. Composé selon l'une quelconque des revendications 3 et 4, pour lequel  $\text{X}$  est le S pour plus de 95 %.
8. Composé selon la revendication 7, dans lequel  $\text{X}$  est le S.
9. Composition pharmaceutique comprenant un composé pour l'inhibition de HTLV-III, répondant à la  
 40 formule II :



20 dans laquelle n est un nombre entier compris entre 5 et 30 et B est choisi parmi l'adénine (A), la guanine (G), la cytosine (C) et la thymidine (T).

25 10. Composition selon la revendication 9, dans laquelle l'oligodésoxyribonucléotide est l'oligo-dC-phosphorothioate possédant d'environ 5 mères à environ 30 mères.

11. Composition selon la revendication 9 dans laquelle l'oligodésoxynucléotide est l'oligo-dA-phosphorothioate possédant d'environ 5 mères à environ 30 mères.

30 12. Composition selon la revendication 9 dans laquelle l'oligodésoxynucléotide est l'oligo-dA-phosphorothioate d'environ 28 mères.

13. Composition selon l'une quelconque des revendications 9 à 12, dans laquelle le support est choisi parmi le sérum physiologique, un support organique ou le sang.

35 14. Composition selon la revendication 9, dans laquelle ledit désoxynucléotide est le didésoxy-2'-3'-adénosine.


40 15. Procédé pour prévenir la réplication et les effets cytopathologiques d'un acide nucléique étranger dans des cellules, in vitro, comprenant l'étape d'exposition des cellules à une quantité suffisante d'un oligodésoxynucléotide de formule II de la revendication 9, pour inhiber la réplication dudit acide nucléique étranger.

45 16. Procédé pour prévenir la réplication d'un acide nucléique étranger dans des cellules vivantes normales, in vitro, comprenant l'étape d'exposition des cellules à une quantité suffisante pour inhiber la réplication, d'un oligodésoxynucléotide de formule I de la revendication 3, selon lequel l'oligodésoxynucléotide possède une séquence de bases complémentaire à une séquence de bases du virus de l'immunodéficience humaine (IVH).

50 17. Composition pharmaceutique comprenant un composé de la formule I de la revendication 3 et un didésoxynucléotide.

18. Utilisation pour préparer un médicament destiné au traitement de maladies causées par l'expression d'un acide nucléique étranger tel qu'un oncogène ou le HTLV-III, ledit médicament comprenant une composition comprenant un composé répondant à la formule I :

55



20 dans laquelle n est un nombre entier compris entre 5 et 30, B est choisi parmi l'adénine (A), la guanine (G), la cytosine (C) et la thymine (T), et X est choisi parmi le S et l'O, à la condition qu'au moins un X dans le composé soit le S, pour obtenir une séquence anti-sens spécifique à une partie dudit acide nucléique étranger.

25 19. Utilisation selon la revendication 18, selon laquelle la maladie est causée par le HTLV-III.

20. Utilisation selon l'une quelconque des revendications 18 et 19, pour laquelle dans deux monomères X est le S et dans les monomères restants X est l'O.

30 21. Utilisation selon la revendication 20, pour laquelle le polymère est coiffé à son extrémité par des monomères dans lesquels X est le S et dans les monomères restants X est l'O.

22. Utilisation selon l'une quelconque des revendications 18 et 19, pour laquelle les monomères dans lesquels X est le S et les monomères dans lesquels X est l'O sont présents en quantités égales.

35 23. Utilisation selon la revendication 18, pour laquelle l'oncogène est un gène C-myc.

24. Utilisation pour préparer une composition destinée à la prévention de maladies causées par la répllication d'acides nucléiques étrangers en présence de cellules vivantes normales, comprenant un oligodésoxynucléotide phosphorothioate dans un support pharmaceutiquement acceptable.

40


25. Utilisation selon la revendication 24, pour laquelle la maladie est causée par le HTLV-III.

26. Utilisation selon la revendication 24 ou 25, pour laquelle l'oligodésoxynucléotide phosphorothioate répond à la formule II.

45

50

55



20 dans laquelle n est un nombre entier compris entre 2 et 30 et B est choisi parmi l'adénine (A), la guanine (G), la cytosine (C) et la thymine (T).

25 27. Utilisation selon la revendication 26, pour laquelle l'oligodésoxynuécléotide est l'oligo-dC-phosphorothioate possédant d'environ 5 mères à environ 30 mères.

28. Utilisation selon la revendication 26, pour laquelle l'oligodésoxynuécléotide est l'oligo-dA-phosphorothioate possédant d'environ 5 mères à environ 30 mères.

30 29. Utilisation selon la revendication 26, pour laquelle l'oligodésoxynuécléotide est l'oligo-dA-phosphorothioate d'environ 28 mères.

30. Utilisation selon la revendication 26, pour laquelle le support pharmaceutiquement acceptable est choisi parmi le sérum physiologique, un support organique, et le sang.

35 31. Utilisation selon la revendication 26, pour laquelle le didésoxynuécléotide est la didésoxy-2'-3'-adénosine.

40

45

50

55

FIG.1




FIG.2





FIG.3

EFFECT OF S-AS ON HL-60 CELL GROWTH



EFFECT OF S-NS ON HL-60 CELL GROWTH




FIG. 4

S-AS (MYC) ODNs INHIBIT DNA SYNTHESIS IN HL-60 CELLS





FIG. 5




Anti-sense: ODN-1: 5'-TCG TCG CTG TCT CC-3'  
 N-Me-ODN-1: 5'-TCG T\*CG CTG T\*CT CC-3'  
 (\* denotes N<sup>3</sup>-methyl-thymidine)

Sense: ODN-3: 5'-CAT AGG AGA TGC CT-3'  
 ODN-2: 5'-GGA GAC AGC GAC GA-3'

Random: ODN-4: 5'-CTG GTT CGT CTC CC-3'  
 dCn: 5'-(dC)<sub>n</sub>-3'  
 dAn: 5'-(dA)<sub>n</sub>-3'

FIG. 6






FIG. 8

